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Abstract The increasing worldwide burden of cancer
makes it imperative that every country develop a com-
prehensive cancer control programme. In the past, cancer
control in Central and Eastern Europe was inadequate,
particularly when compared to many wealthier Western
European countries. We analyse interregional differences
in Europe to the approach to comprehensive cancer care,
with a focus on head and neck squamous cell carcinoma
using the case of Poland as a representative example. Due
to national plans major improvements have been achieved
in the field of prevention and in radiotherapy delivery
having a measurable and positive impact on treatment
outcomes. In head and neck cancers a notable move
towards multidisciplinary approach has been made, com-
bining surgery, radiotherapy and chemotherapy accompa-
nied by rehabilitation and social support. In Poland and
several other Eastern and Central European countries a
shortage of physicians in the field of oncology was noted.
The main conclusion is that the special plans are needed in
Central and Eastern Europe or those existing must be
extended for another decade to fulfil the EU requirement of
providing all European citizens with equal access to quality
cancer care.
Introduction
The burden of cancer is increasing in European countries
due to population ageing and lifestyle choices such as
tobacco and alcohol use, physical inactivity, and poor diets
[1–6]. As a result, demand for cancer care services has
been growing as well. The challenge facing most countries
is how to meet this rising demand as efficiently and
effectively as possible.
These challenges are particularly relevant in cancer care,
especially in times of limited budgets and increasingly
expensive technology and drugs [7–16]. To reduce the
costs associated with providing health care to a large
population, it is essential to develop a comprehensive
approach to cancer control. A substantial percentage of
cancers could be prevented by applying existing cancer
control knowledge to implement effective prevention and
screening programmes and to undertake public health
campaigns to promote physical activity and healthy diets.
However, even though the effectiveness of such interven-
tions is well-known, cancer control in many countries is
woefully inadequate, and morbidity and mortality rates due
to cancer are higher than they need be [3, 6, 17–25].
In the past, cancer control in Central and Eastern Europe
was inadequate, particularly when compared to many
wealthier Western European countries. However, in recent
years, many countries in this region have made a concerted
effort to improve cancer control and care. As a result, the
health care systems in these countries have undergone
several major reforms since the early 1990s to address their
numerous shortcomings [26–29].
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In the present article, we analyse interregional differ-
ences in Europe to the approach to comprehensive cancer
care, with a focus on head and neck squamous cell carci-
noma (HNSCC). The case of Poland is used as a repre-
sentative example for Central and Eastern Europe, where
gross national income (GNI) is significantly lower than in
Western and Northern Europe.
Cancer incidence in Poland and in the European Union
Historically, cancer care outcomes in Central and Eastern
European countries have been below those reported in
Western and Northern European countries [1, 4, 6, 23, 24,
30–32]. In 2003, for example, cancer survival rates in
Poland were only 30 vs. 45 % in Western and Northern
Europe [33–36]. Similarly, the Eurocare-3 study, which
compared 19 European countries to assess associations
between national income, investment in health care, and
survival in patients diagnosed with cancer between 1990
and 1994 (and followed to 1999), found that all-cancer
survival in Poland was lower than countries of similar
wealth, in part due to relatively low spending on health
care as a percentage of gross domestic product [37]. The
EUROCARE-4, which assessed patients from 22 European
countries diagnosed with cancer between 1995 and 1999
and followed to December 2003, reported that the mean
European survival for HNSCC cancers was 48.9 %, with
survival significantly lower in two countries: the United
Kingdom (UK)-Northern Ireland (36.9 %) and Poland
(37.9 %). This compares to higher survival rates found in
Finland (59.7 %), Sweden (56.2 %) and Germany (61.2 %)
[6]. Similarly, that same study found that survival for most
solid cancers (whose prognosis depends on diagnostic
stage), was lowest in the Czech Republic, Poland, and
Slovenia. Publication of the EUROCARE results has
encouraged many countries, among them the UK, Den-
mark, and Poland, to develop a national cancer plan to
improve outcomes.
HNSCC
Head and neck squamous cell carcinoma is a significant
component of the global burden of cancer. Worldwide,
more than 600,000 patients are diagnosed each year with
HNSCC, accounting for 6 % of all cancer cases. Studies
have shown that heavy intake of alcoholic beverages is
associated with nutrient deficiency, which appears to con-
tribute independently to oral carcinogenesis [5]. In the last
two decades, a slight decrease has been noted in the overall
incidence of head and neck cancer, laryngeal cancer in
particular. In contrast, however, a significant increase in
cancers of the oropharynx and oral cavity has been detected
[23, 38]. Oral cancer is particularly high among men, and
more common in developing than developed countries.
Sharp increases in the incidence rates of oropharyngeal
cancers have been noted for several countries and regions,
including Denmark, France, Germany, Scotland, and
Central and Eastern Europe [5].
According to the Central Statistical Office in Poland,
5,645 head and neck cancer deaths were registered in
Poland in 2010 (4,430 men, 1,215 women), constituting an
increase of 11 % compared to 1999. In Poland, H&N
cancer accounts for 8.5 % of cancer deaths in men and 3 %
in women. Patients age 55? accounted for most of those
cancer-related deaths (80 and 85 %, respectively, in men
and women). The raw mortality rate also increased with
age. The male to female incidence ratio of 1.8 shows that
the relative risk of developing H&N cancer is generally
higher in men, as is the relative risk of death (M/F = 3.8),
particularly in the 55–59 age group in which the M/F ratio
rises to 5.8. In most categories, the morbidity/mortality
(MM) ratio is higher than 1, with the exceptions of men
over age 80 and women over age 85. Of particular note is
the 30–34 age group, in which the MM ratio for women is
almost 209 higher than for men [35, 39–41].
Researchers have identified the human papilloma virus
(HPV) as the causative factor for a subset of HNSCC
tumours [42–44], particularly HPV-16, which is especially
common in otopharyngeal tumours. Fortunately, HPV-
associated tumours have better clinical outcomes [43]. As
in many other cancers, oral cancer is preventable by min-
imizing or eliminating risk factors. Prevention of HIV
infection will also reduce the incidence of HIV/AIDS-
related cancers such as Kaposi’s sarcoma and lymphoma.
In 2007, the World Health Assembly passed a resolution
(the WHO Global Oral Health Programme; WHA60 A16)
urging member states to ensure that prevention be included
as a major component of cancer control programmes, along
with the involvement of oral health professionals or pri-
mary health care staff with relevant training in oral health,
in detection, early diagnosis, and treatment [5].
Head and neck cancers are difficult to treat due to their
heterogeneity, location near sensitive organs, and the fact
that treatment is nearly always multidisciplinary [16, 38,
41, 45–47]. Depending on the site and stage of the cancer,
treatment may consist of surgery, radiotherapy, chemo-
therapy or a combination thereof, accompanied by reha-
bilitation and social support [2, 45]. For advanced cases,
there has been a shift from surgical treatment towards
chemoradiotherapy protocols (especially concomitant
chemotherapy and radiotherapy). Systemic therapies (che-
motherapy and targeted molecular agents) have been suc-
cessfully integrated into potentially curative treatment of
locally advanced HNSCC [15, 39, 48, 49]. Major
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improvements have been achieved in radiotherapy delivery
[11, 29, 50–52], and in Poland a recent study found that
investments in more modern radiotherapy equipment had a
measurable and positive impact on treatment outcomes [27,
53, 54]. In deciding which treatment strategy would be
suitable for an individual patient, important considerations
include expected functional outcomes, ability to tolerate
treatment, and comorbid illnesses. Collaboration amongst
many specialties is the key for optimal assessment and
decision-making in the management of HNSCC [38, 46].
Network of comprehensive cancer centres in Poland
In Poland, the largest and most populous country in the
region, a major cancer control initiative was undertaken in
2005 with the implementation of the National Program
against Cancer Diseases (NPACD) [33]. The main aim of
the NPACD was to combat the alarming and increasing
incidence of cancer. To that end, the government allocated
approximately €700 million (PLN 250 million/year) in
funding for the years 2005–2015. In addition to the
aforementioned goal of preventing cancer, the NPACD
also sought to bring Polish cancer care up to European
standards for early cancer diagnosis and treatment, to
accelerate the transfer of the latest research findings from
lab to bed, and to monitor the efficacy of cancer control
activities in Poland.
The current medical care system in Poland is an oblig-
atory public health insurance system. All individuals cov-
ered by general health insurance receive free health
services by private or public health care providers. Con-
tracts are awarded on a regional basis directly by one of the
16 branches of the National Health Fund (NHF) and are
signed for 5 years while reimbursement is negotiated
annually. Patients also have the right to choose their health
care provider, which can be public (mainly hospitals) or
private (individual or group medical practices or regular
commercial entities). Poland joined the EU more than
10 years ago, and the consequent increase in cross-border
patient and staff mobility has increased expectations in
Poland, not only for improved treatment results and greater
comfort in the hospital setting [55].
Since 2009, due to insufficient funds, the NHF has had
difficulties fully reimbursing hospitals. At present, private
hospitals compete with public hospitals on an equal basis
for NHF contracts. However, some have questioned this
rule because even though both private and public hospitals
provide health services to patients at no cost to the patient
(i.e., reimbursed by the NHF), private hospitals are also
allowed to treat and charge private patients outside the
NHF. Public hospitals, in contrast, are not allowed to have
private patients, with only a few exceptions (e.g.,
procedures not covered by the NHF). This is a major
handicap to public providers when the NHF contract is
fulfilled before the end of the year: private providers have
the option to close or limit service while public ones are
forced to continue treating patients, even though they will
not receive any additional funds for doing so, thus wors-
ening their financial condition.
In recent years, the NPACD has provided substantial
funds for investment in new equipment, to develop
screening and prevention programmes (including genetic
screening), to improve cancer registries, and to carry out
epidemiological studies. Other sources of funds include the
National Science Centre and National Centre for Research
and Development, both of which support research projects
through grants, plus local sources of funding that can be
used for investment and prevention/screening.
The existing cancer network consists of comprehensive
cancer centres located in each of the 16 provinces in
Poland. Universities also provide cancer care at their
teaching hospitals through small clinics within these hos-
pitals. Such clinics are legally part of a large multidisci-
plinary teaching hospital, and thus have no financial
autonomy. In the authors’ opinion, some changes in the law
are needed to enable existing cancer centres to become
more involved in academics, either by granting them status
as research institutes or by allowing them to enter the
university as stand-alone centres. At the very least, it would
be important to avoid forcing such centres to be ‘‘diluted’’
as part of general medicine hospitals.
An important issue in Poland—and several other Eastern
and Central European countries—is a shortage of physi-
cians in the field of oncology [27, 56]. As in many other
countries, the discipline of oncology in Poland is subdi-
vided into several different specialities, including onco-
logical surgery (although general surgeons can also operate
on cancer patients), radiation oncology, and medical
oncology. In contrast, in some countries, notably the
Scandinavian countries and the United Kingdom, the spe-
cialties of medical and radiation oncology are combined.
At present, there is much debate about the appropriate
competencies of these various specialities, particularly with
regards to prescribing oral anticancer drugs [7, 57].
One of the drivers of the shortage of specialists in
radiation oncology, in Poland and other countries, is that,
compared to other specialities, fewer students choose this
field for the simple reason that it is introduced towards the
latter part of medical studies, when many students have
already chosen their preferred specialities [53, 57]. Since
2009, the NPACD has required that all universities in
Poland provide at least 15 contact hours of basic oncology
in the 3rd year curriculum of the degree in medicine, and
60 contact hours of oncology in the 6th year. Finally,
another challenge relates to awareness and training of
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university students who are studying fields (other than
medicine) in which an understanding of oncology is—or
should be—important. Such fields include medical physics,
physiotherapy, nursing, public health, pharmacy, biotech-
nology, and many others. The process of incorporating
oncology into the curriculum, both as an undergraduate
course for future physicians and for other medical disci-
plines, is ongoing [27, 57, 58].
Conclusion
As we have seen in the case of Poland, Eastern and Central
European countries have undertaken comprehensive changes
and increased spending to improve their cancer control and
treatment efforts in recent decades. The result is a much
improved health care system with comprehensive cancer
control efforts and improved technology and training.
However, unlike Poland, not all countries in the Euro-
pean Union have the funds to invest in more modern
equipment and facilities, particularly in Central and East-
ern Europe. However, countries with fewer resources can
still greatly improve health care outcomes. Research by the
WHO and other international bodies has shown that the
most cost-effective way to improve outcomes and to reduce
the burden of cancer is through coordinated prevention and
early detection efforts. This approach offers countries a low
cost but effective way to control cancer, and it has been
successfully implemented in Poland. At the same time,
however, prevention and detection also require well-run
national and regional cancer registries to keep track of
changes, and so it is imperative that countries seeking to
improve cancer control implement a coordinated approach
to preventing and treating cancer.
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